CXCR3 and neoplasm: This reduction in CD8+ T cell recruitment upon CXCR3 blockade also mitigated the anti-tumor effects of combined EZH2 suppression and T/P-induced senescence and reversed PDAC tumor regressions (Fig. 6k).